Login
$AVR
$5.70 +$0.28 (5.17%) Live

Company Executives

Officer Age In this role 2025 pay Source
Wayne Paterson Also a director
Vice Chairman and Chief Executive Officer
60 Not stated $6,131,101
Brent Moen
Chief Financial Officer
59 Since 2026
this year
Not reported
David St Denis Also a director
President, Director
58 Since 2025
1 year
$981,905
Matthew McDonnell
Head of Australia
54 Since 2026
this year
$457,352

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
4 of 7
stated in the proxy
Average tenure
5.0 years
from year joined
CEO also chairs the board
No
John Seaberg
Director Age On board Independent Committees Other public boards 2025 pay Source
John Seaberg
75 2014
12 years
Independent
Audit and Risk Committee
None stated $777,314
Wayne Paterson
60 2014
12 years
Not independent None stated None stated Paid as CEO
David St Denis
58 2025
1 year
Not independent None stated None stated Not stated
Stephen Denaro
65 2018
8 years
Not independent None stated None stated $436,622
Gregory Moss
43 2025
1 year
Independent
Audit and Risk Committee
None stated $329,346
Susan Knight
71 2026
this year
Independent
Audit and Risk Committee · Chair
None stated Not stated
David Roberts
62 2025
1 year
Independent
Nominating and Corporate Governance Committee · Chair
LeMaitre Vascular, Inc. $334,098

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Nov 9, 2026
Medtronic (Covidien Group S.à r.l.)
Amount not stated
January 2026

Stock purchase agreement under which the Company agreed to sell 15,652,173 shares of Common Stock to Medtronic in a private placement.

With the Company Open in proxy
Medtronic (Covidien Group S.à r.l.)
Amount not stated
January 2026

Registration rights agreement requiring the Company to file a resale registration statement for Medtronic's shares, with liquidated damages payable if registration fails, capped at 5.0% of the purchase price.

With the Company Open in proxy
Medtronic (Covidien Group S.à r.l.)
Amount not stated
January 2026

Investor rights agreement granting Medtronic participation rights, transfer restrictions, a collaboration framework, standstill, voting agreement, board observer right and a right to negotiate.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support